News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Comparative Trial of Canyon Pharmaceuticals's Iprivask (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT


4/15/2010 9:36:39 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--Results of the first randomized, head-to-head comparison of direct thrombin inhibitors (DTIs) in patients with heparin-induced thrombocytopenia (HIT) were presented at the Hemophilia & Thrombosis Research Society 2010 Scientific Symposium in Chicago, Illinois on April 15. The PREVENT-HIT study found that desirudin warrants further investigation as an alternative treatment for thrombosis prophylaxis in surgery patients with HIT.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES